>>8790921 (Q)
>https://twitter.com/earth_pupil/status/1250117044789370880
>Hydroxychloroquine+
QProof 3956 (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
DJ Wallace
Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, California, USA
First Published June 1, 1996
https://doi.org/10.1177/0961203396005001131
Abstract
Chloroquine and hydrocychloroquine have been evaluated in 30 noninfectious disorders and conditions other than rheumatoid arthritis or lupus erythematosus; 12 of these have been subjected to well-designed controlled trials. It is concluded that chloroquines are safe and effective first line therapies for selected patients with porphyria cutanea tarda, cutaneous sarcoidosis, cutaneous manifestations of dermatomyositis, hyperlipidemias and thromboembolic prophylaxis for patients with antiphospholipid antibodies. Published experience with these and other diseases or syndromes are critically reviewed.
notable excerpts:
Hyperlipidemia
Wallace et al. followed 150 lupus and rheumatoid arthritis patients and found that those taking hydroxychloroquine had significantly lower LDL, serum triglyceride and cholesterol levels, or a 15-20% decrease. The drug also decreased the lipid raising effects of corticosteroids. Hodis et al.’s group at the University of Southern California and Blyth et al. in Glasgow confirmed these findings with nearly 100 lupus and rheumatoid arthritis patients.
Powrie et al. demonstrated similar changes among diabetics given short term high dose quinacrine or chloroquine. A prospective analysis of 264 patients in Table 1 Documentation of studies using chloroquines to treat noninfectious disorders other than rheumatoid arthritis or lupus erythematosus the Petri et al.’s Baltimore lupus cohort clearly showed that hydroxychloroquine therapy was associated with lower serum cholesterol.
Diabetes mellitus
Occasional reports of symptomatic hypoglycemia in patients receiving chloroquine and work suggesting that its ability to raise intracytoplasmic pH interfered with insulin receptors led Quartaro to evaluate its effects in diabetes. Thirty-eight patients with refractory noninsulin dependent diabetes were randomized into four groups: oral agents or insulin with or without 600 mg of hydrochloroquine a day for six months. Patients receiving hydroxychloroquine with insulin had the most favorable glycated Hb Al, profiles and the lowest insulin requirements. Powrie studied 20 patients with three days of the rather large dose of 250 mg of chloroquine four times a day and compared them with placebo. This dose decreased mean plasma glucoses by 35mg/dl and decreased insulin clearance rates by 39%. Petri et al. found mean glucoses among 282 lupus patients at 3397 outpatient visits were 5 mg/dl less in those taking hydroxychloroquine than those not taking it (P = 0.04).
What about the billions (public/private/govt) provided to fund cure dev? ~Q